Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-10-16 Sale | 2024-10-17 4:30 pm | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $16 | $200,000 | 815,529 (Indirect Direct) | View |
| 2024-08-20 Sale | 2024-08-21 6:49 pm | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $16 | $200,000 | 828,029 (Direct) | View |
| 2022-11-29 Purchase | 2022-12-01 4:31 pm | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 8,250 | $6.2432 | $51,506 | 8,250 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-12-06 Option Award | 2024-12-10 9:56 pm | N/A 2034-12-06 | NKGen Biotech Inc. | NKGN | Scott Kathleen D. Director | 800,000 | $0 | 800,000 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-17 4:30 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $1.5 | 815,529 (Direct) | View |
| 2024-10-16 Exercise | 2024-10-17 4:30 pm | N/A 2032-02-29 | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $0 | 815,529 (Direct) | View |
| 2024-08-20 Exercise | 2024-08-21 6:49 pm | N/A N/A | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $1.5 | 828,029 (Direct) | View |
| 2024-08-20 Exercise | 2024-08-21 6:49 pm | N/A 2032-02-29 | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 12,500 | $0 | 828,029 (Direct) | View |
| 2024-02-12 Option Award | 2024-02-14 8:20 pm | N/A N/A | NKGen Biotech Inc. | NKGN | Scott Kathleen D. Director | 300,000 | $0 | 300,000 (Direct) | View |
| 2024-01-04 Option Award | 2024-01-05 9:01 pm | N/A 2034-01-03 | Dermata Therapeutics Inc. | DRMA | Scott Kathleen D. Director | 10,000 | $0 | 10,000 (Direct) | View |
| 2024-01-02 Option Award | 2024-01-04 4:39 pm | N/A 2034-01-01 | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 200,000 | $0 | 200,000 (Direct) | View |
| 2023-01-03 Option Award | 2023-01-05 5:00 pm | N/A 2033-01-02 | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 50,000 | $0 | 50,000 (Direct) | View |
| 2022-11-08 Option Award | 2022-11-10 6:00 pm | N/A 2032-03-01 | ARS Pharmaceuticals Inc. | SPRY | Scott Kathleen D. Chief Financial Officer | 827,330 | $0 | 827,330 (Direct) | View |
| 2022-10-06 Option Award | 2022-10-07 5:05 pm | N/A N/A | Dermata Therapeutics Inc. | DRMA | Scott Kathleen D. Director | 11,359 | $0 | 29,584 (Direct) | View |
| 2022-07-07 Option Award | 2022-07-08 4:10 pm | N/A N/A | Dermata Therapeutics Inc. | DRMA | Scott Kathleen D. Director | 9,960 | $0 | 18,225 (Direct) | View |
| 2022-04-07 Option Award | 2022-04-08 7:17 pm | N/A N/A | Dermata Therapeutics Inc. | DRMA | Scott Kathleen D. Director | 5,826 | $0 | 8,265 (Direct) | View |
| 2022-01-03 Option Award | 2022-01-05 7:05 pm | N/A 2032-01-02 | Dermata Therapeutics Inc. | DRMA | Scott Kathleen D. Director | 5,000 | $0 | 5,000 (Direct) | View |
| 2021-08-17 Option Award | 2021-08-17 12:47 pm | N/A 2031-08-17 | Dermata Therapeutics Inc. | DRMA | Scott Kathleen D. Director | 10,000 | $0 | 10,000 (Direct) | View |
Ownership | 2021-08-12 7:47 pm | N/A N/A | Dermata Therapeutics Inc. | DRMA | Scott Kathleen D. Director | 0 | $0 | 2,439 (Indirect) | View |